Tremfya Industry Report 2025-2034: Market Dynamics, Drivers, And Forecasts

We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.

What Is the Projected Growth of the Tremfya Market?
In more recent times, the market size for Tremfya has experienced a growth of XX (HCAGR). There is an expected increase from $XX million in 2024 to $XX million in 2025, reflecting a compound annual growth rate (CAGR) of XX%. Factors that have contributed to this trajectory of growth within the historic period comprise the increasing occurrences of psoriasis and psoriatic arthritis, an escalated emphasis on targeted treatments, rising investments in health care, increased specialty clinic availability, and a surge in the adoption of biological products in the fields of dermatology and rheumatology.

Expectations are set for the tremfya market to witness an XX (FCAGR) in the near future. By 2029, it is projected to surge to a worth of $XX million, with a compound annual growth rate (CAGR) of XX%. The increase during the forecast period is due to factors such as: enhancement in healthcare infrastructure, adoption of point-of-care testing boosted, healthcare research seeing a rise in investments, and more emphasis put on precision medicine. The major trends seen within this forecast period include progresses in treatment modalities, personalisation of medicine methods, technological incorporation in patient monitoring, the inclusion of artificial intelligence (AI), and developments in injection devices.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20343

What Are the Different Tremfya Market Segments?
The tremfya market covered in this report is segmented -

1) By Indication: Moderate-To-Severe Plaque Psoriasis; Active PsA
2) By Formulation: Subcutaneous Injection; Intravenous Infusion
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies
4) By End User: Adult Patients; Geriatric Patients

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20343&type=smp

What Are the Primary Drivers Shaping the Tremfya Market?
The escalating occurrence of autoimmune diseases is predicted to drive the expansion of the tremfya market in the future. These diseases, where the body's immune system wrongfully targets its own cells, tissues, or organs, are rising due to genetic predisposition, environmental factors, changes in lifestyle, heightened awareness, and enhanced diagnostic methods. Tremfya, a monoclonal antibody that focuses on interleukin-23 (IL-23), aids in managing these diseases by moderating the immune system's heightened response, lessening inflammation, and easing symptoms in conditions like psoriasis and psoriatic arthritis. As an example, a report in June 2024 by the Australian Institute of Health and Welfare, a government organization in Australia, revealed that there were 10,000 hospitalizations for rheumatoid arthritis in 2022, signifying a 25% rise from 8,000 the previous year, with a hospitalization rate of 39 per 100,000 individuals. As such, the escalating occurrence of autoimmune diseases is propelling the expansion of the tremfya market.

Which Companies Are Leading in the Tremfya Market?
Major companies operating in the tremfya market are Johnson & Johnson

What Trends Are Driving Growth in The Tremfya Market?
A significant development in the Tremfya market is its increasing reception of regulatory approvals to widen its therapeutic applications, such as in the treatment of moderate-to-severe Crohn's disease, thereby enlarging its target audience and market scope. Regulatory approvals entail the formal permission given by authoritative bodies like the Food and Drug Administration (FDA) or European Medicines Agency (EMA) that enable a drug to be used commercially for particular uses once its safety, effectiveness, and quality are proven. For instance, in September 2024, Johnson & Johnson, a pharmaceutical firm based in the US, acquired FDA approval to use TREMFYA (guselkumab) in treating adults with moderately to severely active ulcerative colitis, earning it the distinction of being the first interleukin-23 inhibitor with dual-action to gain approval for this usage. This decision stems from the encouraging results of the Phase 2b/3 QUASAR study, which determined that around 50% of patients went into clinical remission after 44 weeks of treatment. TREMFYA acts by targeting interleukin-23, thereby helping to regulate the inflammatory response in the colon.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/tremfya-global-market-report

What Are the Top Revenue-Generating Geographies in the Tremfya Market?
North America was the largest region in the tremfy market in 2024. The regions covered in the tremfya market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Tremfya Market?
2. What is the CAGR expected in the Tremfya Market?
3. What Are the Key Innovations Transforming the Tremfya Industry?
4. Which Region Is Leading the Tremfya Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.